Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease. Mark PB, Sattar N. Lancet 2022 Nov 4. pii: S0140-6736(22)02164.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mark PB, Sattar N. Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease. Lancet 2022 Nov 4. pii: S0140-6736(22)02164.
PMID: 36351457